Pfizer to Acquire Metsera for $86.25 Per Share in $10 Billion Deal
Biotech buyout ends bidding war with Novo Nordisk, securing key obesity drug assets. New York – November 8, 2025 — Pfizer Inc. has finalized a deal to acquire Metsera, a clinical-stage biotech focused on obesity treatments, for $86.25 per share in cash, representing a 3.69% premium over Metsera’s closing price on Friday CNBC. The transaction […]
Continue Reading